Comparison of atovaquone and azithromycin with trimethoprim- sulfamethoxazole for the prevention of serious bacterial infections in children with HIV infection

Clinical Infectious Diseases

Volumn 40, Issue 1, 2005, Pages 136-145

  Hughes, Walter T ^a   Dankner, Wayne M ^b   Yogev, Ram ^c   Huang, Sharon ^d   Paul, Mary E ^e   Flores, Midnela Acevedo ^f   Kline, Mark W ^f   Wei, Lee Jen ^d  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CHILDREN'S MEMORIAL HOSPITAL   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f Department of Pediatrics   (Puerto Rico)

Author keywords

[No Author keywords available]

Indexed keywords

ATOVAQUONE; AZITHROMYCIN; COTRIMOXAZOLE;

ADOLESCENT; ANEMIA; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; BACTERIAL STRAIN; BLOOD TOXICITY; CHILD; CHILDHOOD DISEASE; CHILDHOOD MORTALITY; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELECTROLYTE DISTURBANCE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; LIVER TOXICITY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYCOBACTERIOSIS; MYCOBACTERIUM INTRACELLULARE AVIUM; NEPHROTOXICITY; NEUTROPENIA; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS CARINII; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; THROMBOCYTOPENIA;

ADOLESCENT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ATOVAQUONE; AZITHROMYCIN; BACTERIAL INFECTIONS; CHILD; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; MALE; NAPHTHOQUINONES; PNEUMONIA, PNEUMOCYSTIS; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 11144221175     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/426074     Document Type: Article

References (32)

1. Hughes WT, Kuhn S, Chaudhary S, et al. Successful chemoprophylaxis for Pneumocystis carinii pneumonias. N Engl J Med 1977; 297:1419-26.
2. Fischl MA, Dickinson GM, La Voie L. Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS. JAMA 1988; 259:1185-9.
3. Klein RS. Prophylaxis of opportunistic infections individuals infected with HIV. AIDS 1989; 3(Suppl 1):S161-73.
4. Masur H, Michelis MA, Green JB, et al. An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction. N Engl J Med 1981; 305:1431-8.
5. Gottlieb MS, Schroff R, Schanker HM, et al. Pneumocystis cariniipneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med 1981; 305:1425-31.
6. US Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention. Guidelines for prophylaxis against Pneumocystis carinii pneumonia in persons infected with human immunodeficiency virus. MMWR Morb Mortal Wkly Rep 1989; 38:1-9.
7. Hardy WD, Feinberg J, Finkelstein DM, et al. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. N Engl J Med 1992; 327:1842-8.
8. Spector SA, Gelber RD, McGrath N, et al. A controlled trial of intravenous immune globulin for the prevention of serious bacterial infections in children receiving zidovudine for advanced human immunodeficiency virus infection. N Engl J Med 1994; 331:1181-7.
9. Hughes WT, Armstrong D, Bodey G, et al. Infectious Diseases Society of America guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 1990; 161:381-96.
10. Gordin FM, Simon GL, Wofsy CB, Mills J. Adverse reactions to trimethoprim-sulfamethoxazole in patients with acquired immunodeficiency syndrome. Ann Intern Med 1984; 100:495-9.
11. Centers for Disease Control and Prevention. 1994 Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. Official authorized addenda: human immunodeficiency virus infection codes and official guidelines for coding and reporting ICD-9-CM. MMWR Morb Mort Wkly Rep 1994; 43(RR-12): 1-17.
12. Centers for Disease Control and Prevention. Revised guidelines for prophylaxis against Pneumocystis carinii infection for children infected with perinatally acquired HIV. MMWR Mort Morb Wkl Rep 1995; 44(RR-4):11.
13. Wei LJ, Lin DY, Weissfeld LA. Regression analysis of multivariate incomplete failure time data by modeling marginal distributions. J Am Statistical Assoc 1989; 84:1065-73.
14. Andersen PK, Gill RD. Cox regression model for counting processes: a large sample study. Ann Statist 1982; 10:1100-20.
15. Scott GB, Hutto C, Makuch RW, et al. Survival in children with perinatally acquired human immunodeficiency virus type 1 infection. N Engl J Med 1989; 321:1791-6.
16. Oxtoby MJ. Perinatally acquired human immunodeficiency virus infection. Pediatr Infect Dis J 1990; 9:609-19.
17. Principi N, Marchisio P, Tornaghi R, et al. Acute otitis media in human immunodeficiency virus-infected children. Pediatrics 1991; 88:566-71.
18. Barnett ED, Klein JO, Pelton SI, Luginbuhl LM. Otitis media in children born to human immunodeficiency virus-infected mothers. Pediatr Infect Dis J 1992; 11:360-4.
19. Dankner WM, Lindsey JC, Levin MJ. Correlates of opportunistic infections in children infected with human immunodeficiency virus managed before highly active antiretroviral therapy. Pediatr Infect Dis J 2001; 20:40-8.
20. El-Sadir W, Murphy RL, Yurik RM, et al. Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. N Engl J Med 1998; 339:1889-5.
21. Chan C, Montaner J, Lefebvre E-A, et al. Atovaquone suspension compared with aerosolized pentamidine for the prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected subjects intolerant of trimethoprim or sulfonamides. J Infect Dis 1999; 180:369-76.
22. Havlir DV, Dube MP, Sattler FR, et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. N Engl J Med 1996; 335:392-8.
23. Hughes WT, Leoung G, Kramer F, et al. Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. N Engl J Med 1993; 328:1521-7.
24. Dohn MN, Weinberg WG, Torres RA, et al. Oral atovaquone compared with intravenous pentamidine for Pneumocystis carinii pneumonia in patients with AIDS. Ann Intern Med 1994; 121:174-80.
25. Hughes WT, Dorenbaum A, Yogev R, et al. Phase 1 safety and pharmacokinetics study of micronized atovaquone in human immunodeficiency virus-infected infants and children. Antimicrob Agents Chemother 1998; 42:1315-8.
26. Simonds RJ, Oxtoby MJ, Calldwell B, Gwinn ML, Rogers MF. Pneumocystis carinii pneumonia among US children with perinatally acquired HIV infections. JAMA 1993; 270:470-3.
27. Principi N. Multicentre comparative study of the efficacy and safety of azithromycin compared with amoxicillin-clavulanic acid in the treatment of paediatric patients with otitis media. Eur J Clin Microbiol Infect Dis 1995; 14:669-76.
28. USPHS-IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. US Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA). MMWR Morb Mortal Wkly Rep 1999; 48(RR-10):1-59.
29. Nahata MC, Koranyi KI, Luke DR, Foulds G. Pharmacokinetics of azithromycin in pediatric patients with acute otitis media. Antimicrob Agents Chemother 1995; 39:1875-7.
30. Ngo LY, Yogev R, Dankner WM, et al. Pharmacokinetics of azithromycin alone and with atovaquone in human immunodeficiency virus-infected children. Antimicrob Agents Chemother 1999; 43:1516-9.
31. Hughes WT, LaFon SW, Scott JD, Masur H. Adverse effects associated with trimethoprim-sulfamethoxazole and atovaquone during the treatment of AIDS-related Pneumocystis carinii pneumonia. J Infect Dis 1995; 171:1295-301.
32. Centers for Disease Control and Prevention. Guidelines for the prevention of opportunistic infections among HIV-infected persons. MMWR Morb Mort Wkly Rep 2002; 51(RR-08):1-46.